Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations

Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations

Abstract Early Post‐Marketing Phase Vigilance (EPPV) is a unique system that encourages reporting of serious adverse reactions for medications newly introduced to Japan. When a once‐monthly paliperidone palmitate formulation (PP1M) was introduced in Japan in 2013, EPPV detected a signal of increased...

Full description

Bibliographic Details
Main Authors: Daniel Fife, Stephen Fortin, Hong Qiu, Michiyo Yamazaki, Dean Najarian, Erica A Voss
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Neuropsychopharmacology Reports
Subjects:
baseline characteristics
differences
early adopters
long‐acting paliperidone
Online Access:https://doi.org/10.1002/npr2.12260

Similar Items

Similar Items